JNJ 6143 Tests Induced Proximity in Prostate Cancer
Source-gap recovery: Johnson & Johnson’s 25 October ESMO Phase I disclosure, absent from the reviewed Insilens history, provides first human activity for its Halda-derived RIPTAC platform. The single-arm, selected-dose results are hypothesis-generating rather than…
